RxDoctor Payments Data

Romel Wrenn, MD

Interventional Cardiology · Fairbanks, AKNPI 1255302717

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $16,882 of the $21,821 with a category attached, or 77.4%. 26 manufacturers reported payments, led by Siemens Medical Solutions USA, Inc. at 52.1% of the total. Reporting peaked in 2019 at $14,537 and has fallen 70.9% since, to $4,237 in 2025.

$21,821in general payments, 2019–2025

Across 151 payments — averaging $144.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$11K
  • Abbott$3K
  • Medtronic$2K
  • GE HealthCare$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • AstraZeneca$276
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$16,88277%
  • Food & beverage$4,93923%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional cardiology providers in Alaskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$280,486
Medicare patients
1,723
Services billed
3,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban226$342,163
XareltoRivaroxaban46$69,562
Repatha SureclickEvolocumab42$61,200
EntrestoSacubitril/Valsartan42$57,208
BrilintaTicagrelor29$34,367
JardianceEmpagliflozin16$25,216
MultaqDronedarone Hcl11$22,956
Metoprolol Succinate271$5,505
Rosuvastatin Calcium140$2,213
Losartan Potassium166$1,989
Atorvastatin Calcium160$1,933
Carvedilol124$1,429
Ezetimibe70$1,408
Potassium Chloride55$1,353
Labetalol Hcl28$1,245

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$154$342,163226 claims
Johnson & JohnsonXarelto$63$69,56246 claims
NovartisEntresto$270$57,20842 claims
AstraZenecaBrilinta$276$34,36729 claims
Boehringer IngelheimJardiance$32$25,21616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few interventional cardiology providers in Alaskaon file to place this against a meaningful peer group, so we don't.

Other interventional cardiology in Fairbanks

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →